Showing results (201-210 of 307) with videos related to

Sort By:
Pageof 31
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 15, 2003
Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literatureJ E Losa, J M Miro, A Del Rio, et al.
AIDS (London, England)|August 28, 1999
Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replicationF García, G Niebla, J Romeu, et al.
QJM : Monthly Journal of the Association of Physicians|March 5, 2003
Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosaF Vidal, J Mensa, M Almela, et al.
Medicina Intensiva|December 25, 2012
[Antifungal prophylaxis in the postoperative period of lung transplant surgery in Spain]J Sacanell, T Rey, E López, et al.
AIDS (London, England)|August 16, 2001
Lymphoid tissue viral burden and duration of viral suppression in plasmaE Martínez, M Arnedo, V Giner, et al.
Journal of Neurovirology|November 28, 2008
Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-upS Villar del Saz, O Sued, V Falcó, et al.
Medicina Intensiva|August 3, 2012
Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapyJ Rello, S Gattarello, J Souto, et al.
HIV Medicine|January 25, 2011
Influenza A H1N1 in HIV-infected adultsE Martínez, M A Marcos, I Hoyo-Ulloa, et al.
The Journal of Antimicrobial Chemotherapy|August 23, 2007
Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analoguesA León, E Martinez, M Sarasa, et al.
HIV Medicine|February 26, 2015
Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialA C Achhra, A Mocroft, M J Ross, et al.
Pageof 31